DIM (Diindolylmethane).

Glucobrassicin is the indole glucosinolate that yields indole-3-carbinol, which condenses under stomach acid to form DIM. The two are the start and end of the same chemical route.

Sulforaphane comes from glucoraphanin in the same crucifer while DIM comes from glucobrassicin, and sulforaphane acts mainly through Nrf2-driven phase II enzyme induction. Combining them covers two different arms of the crucifer response.

Broccoli sprout extract carries glucoraphanin and glucobrassicin together, so it supplies the precursor pool that a purified DIM dose does not. Formulas pair the isolate with the whole extract for that breadth.

Glucosinolates are the intact sulfur glycosides in crucifers that myrosinase converts to the active indoles and isothiocyanates. DIM is one downstream product of that conversion.

DIM shifts hormone hydroxylation toward the 2-hydroxy route, and calcium D-glucarate releases glucaro-1,4-lactone which slows beta-glucuronidase so glucuronide conjugates stay intact for excretion. One changes the hydroxylation pattern and the other protects the conjugate downstream.

The 2-hydroxy metabolites that DIM favours are methylated by catechol-O-methyltransferase, which uses S-adenosylmethionine as its methyl donor. Supplying the donor supports the step that follows DIM's action.

Catechol-O-methyltransferase requires magnesium as its metal cofactor to transfer a methyl group onto catechol metabolites. That places magnesium directly in the pathway DIM feeds into.

5-methyltetrahydrofolate hands its methyl group to homocysteine to regenerate methionine and then S-adenosylmethionine. It keeps the methyl donor pool stocked for the methylation step downstream of DIM.

Methionine synthase needs cobalamin to move the methyl group from folate onto homocysteine, regenerating the methyl donor pool. Without it the folate methyl group cannot be used.

Betaine donates a methyl group to homocysteine through betaine-homocysteine methyltransferase, a folate-independent route to methionine. It is the second way to keep the methyl pool supplied for catechol methylation.

Quinone intermediates formed from catechol metabolites are cleared by glutathione conjugation, and cysteine availability is what limits glutathione synthesis. NAC supplies that rate-limiting cysteine.

Glutathione S-transferases attach glutathione to reactive quinone intermediates so they can be excreted. That is the disposal step behind the hydroxylation shift DIM produces.

Silymarin flavonolignans raise glutathione availability and support conjugation capacity in liver tissue. Formulas combine it with DIM to cover the clearance side of hormone metabolite handling.

Secoisolariciresinol diglucoside is converted by gut bacteria to enterolignans that bind weakly at estrogen receptors and raise sex hormone binding globulin. That is a different lever from DIM's effect on hydroxylation.

DIM is poorly water soluble and its absorption depends on being taken with lipid or delivered in a microencapsulated matrix. A medium-chain triglyceride carrier is the common way to solve that.

Phospholipids form mixed micelles that hold lipophilic compounds such as DIM in a dispersible form. This is the basis of the enhanced-absorption DIM preparations.

Indoles from crucifers induce CYP1A2, the enzyme that carries out most caffeine demethylation. Regular DIM intake can shorten how long a given caffeine dose stays around, so the two interact even though they share no target.

DIM is not present in intact cruciferous vegetables. Chewing releases myrosinase, which converts glucobrassicin to indole-3-carbinol, and stomach acid then condenses two molecules of I3C into DIM. Supplementing I3C means relying on that acid condensation step, whereas supplementing DIM skips it.

Crystalline DIM is poorly water-soluble and absorbs erratically from a plain powder. Bioavailability-enhanced preparations disperse it in a matrix that typically includes vitamin E as d-alpha-tocopheryl polyethylene glycol succinate alongside a phospholipid. The vitamin E derivative acts as a solubiliser here, not as an antioxidant partner.

Piperine slows several intestinal and hepatic clearance routes, including glucuronidation and some CYP-mediated steps, which is why it appears in so many lipophilic botanical products. Applied to DIM, that would be expected to raise systemic exposure. No study has measured piperine with DIM specifically, so the reasoning is mechanistic.

Catechol oestrogen metabolites formed downstream of the hydroxylation step are cleared largely by methylation, which draws on S-adenosylmethionine and therefore on an intact one-carbon cycle. Pyridoxal-5-phosphate is a required cofactor in that cycle and in the transsulfuration branch that follows. Supporting the methylation side is standard practice when DIM is used to shift metabolite ratios.

Methylenetetrahydrofolate reductase carries FAD as its cofactor, and FAD comes from riboflavin. Without adequate riboflavin the folate cycle that feeds methyl groups to catechol-O-methyltransferase runs less efficiently. This is textbook cofactor dependence rather than an interaction specific to DIM.

Choline feeds the betaine route that remethylates homocysteine to methionine, one of the two ways the body regenerates S-adenosylmethionine. That methyl pool is what catechol-O-methyltransferase draws on when it caps oestrogen metabolites. Choline therefore supports the downstream side of the same normal pathway DIM sits upstream of.

Glutathione peroxidases are selenoproteins, and they sit alongside glutathione S-transferase in the phase II handling of reactive intermediates. DIM is described as inducing the phase II arm through Nrf2 signalling, which only translates into activity if the enzymes have their cofactors. Selenium status is one of the limiting inputs.

Quercetin inhibits several sulfotransferase and UGT isoforms and is itself a substrate for them, so it competes for the same conjugation capacity that handles DIM and its downstream metabolites. The net direction of that competition depends on dose and on which isoform dominates. It is worth flagging rather than assuming an additive effect.

EGCG is a catechol and both a substrate and an inhibitor of catechol-O-methyltransferase, the enzyme that caps catechol oestrogen metabolites with a methyl group. Loading that enzyme with a competing catechol works against the downstream half of what DIM users are usually aiming at. The interaction is well described in enzyme work; nobody has measured the pair in people.

Both DIM and resveratrol interact with the aryl hydrocarbon receptor, DIM as a ligand and resveratrol largely as an antagonist at that receptor. Combining them means pushing the same receptor in opposing directions. The interaction is documented in cell work and its net effect in people is not established.

Conjugated oestrogens excreted in bile can be deconjugated by bacterial beta-glucuronidase and reabsorbed, so the composition of the gut flora shapes how much is recirculated. That is the same enterohepatic loop DIM's metabolite work sits alongside. Which strains shift the loop in which direction is not settled.

Viscous fibre binds bile components and increases faecal loss of conjugated steroids rather than letting them be deconjugated and reabsorbed. This supports the excretion side of normal oestrogen handling, which is downstream of where DIM acts. The two are complementary in mechanism and have not been studied together.

Inulin shifts the composition of the colonic microbiota and with it the pool of bacterial enzymes that act on conjugated steroids reaching the gut. That is a plausible lever on the same enterohepatic loop. The direction of the net effect depends on which organisms expand, so this is mechanistic rather than measured.

Many of the transcription factors and enzymes in phase I and phase II handling, including the alcohol and aldehyde dehydrogenase families and numerous zinc-finger regulators, require zinc structurally. Adequate zinc status is a background requirement for the induction DIM is described as producing. It is a permissive condition, not an additive effect.

Methionine is the direct precursor of S-adenosylmethionine, the universal methyl donor that catechol-O-methyltransferase uses. Methylation is the main capping step for the catechol metabolites formed downstream of DIM's described effect on hydroxylation. Adequate methionine and the B vitamins that recycle it are what let that step run.